ArticleFrontiers in molecular biosciences2026
Metabolomic profiling of Ashwagandha (Withania somnifera): linking bioactive compounds to functional therapeutic roles.
Article in Frontiers in molecular biosciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Aim: To perform comprehensive metabolomic profiling of Methods: Root extracts of Withania somnifera (Ashwagandha) were subjected to methanol-based organic phase extraction followed by LC-MS/MS analysis, resulting in the characterization of 1,020 metabolites. Among these, 1,010 compounds were classified as putatively annotated (MSI Level 2/3 annotations) metabolites based on MS1 data, while 10 highly abundant metabolites were further confirmed by MS/MS fragmentation and assigned MSI Level 2 annotations. Relative abundance analysis was performed to determine the predominant phytochemical constituents of the extract. Key metabolites identified through this approach were subsequently correlated with the known pharmacological properties of Ashwagandha, including its immunomodulatory, anti-inflammatory, antioxidant, adaptogenic, and neuroprotective effects. Results: The analysis identified a diverse array of secondary metabolites, many present at low individual abundance ( Conclusion: Metabolomic profiling of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.